2017 Congress on CVD Prevention

2017 Congress on CVD Prevention

September 15, 2017 to September 17, 2017

The Westin Fort Lauderdale Beach
Fort Lauderdale, FL

The ASPC's 2017 Congress on CVD Prevention being held September 15-17, 2017 at the Westin Fort Lauderdale Beach in Fort Lauderdale, Florida will feature innovative education, ground-breaking science and interactive discussions with top prevention experts. Attendees will have the opportunity to network with faculty and peers, and will leave with practical and useful information to use in clinical practice.

Reasons to Attend:

  • Review the latest advances, current trends and innovative therapies
  • Cutting-edge evidence-based lectures
  • Scientific abstracts and expanded poster hall
  • Pre-congress advanced course on preventive cardiology

Register for the 2017 Congress

Personal Information

Contact Information

Registration

ASPC Member
Not a Member? Click here to become a ASPC member and receive the Member Price.
$325.00
Non-Member
$425.00
Fellow-in-Training Must be logged in to get the Trainee Price.
Not a Member? Click here to become a ASPC member and receive the Trainee Price.
$150.00
Industry Representative
$550.00
Current Fellow of the ASPC (FASPC) Must be logged in
$0.00
Not Attending this Session

Upload Letter of Verification*

*Trainees must attach a letter of verification from program director to qualify for the trainee rate. Accepted file types include DOC, DOCX, and PDF.

Guest Pass- Exhibit Hall $150 x

Can't attend the meeting?
Click here to register for the live streaming of the Congess Meeting. The live streamed version is accredited for 13.25 CME 13.1-13.25 CE, the same number of hours for attending the meeting. In-training members receive complimentary registration to the live streaming version.

Pre-Conference Workshop PC Expert's Course - September 14-15, 2017

ASPC Member $325.00
Current Fellow of the ASPC $325.00
Non-Member $425.00
Fellow-in-Training Must be logged in to get the Trainee Price.
Not a Member? Click here to become a ASPC member and receive the Trainee Price.
$150.00
Industry Representative $500.00
Not Attending this Session

Symposium

Do you plan to attend this free Symposium?

Independent Dinner Non-CME Activity
Friday, September 15, 2017, 6:45 - 8:30 PM
ASPC 2017 Town Hall Series - PCSK9 Inhibitor Access Barriers: Issues and Recommendations: Improving the Access Process for Patients, Clinicians and Payers

Do you plan to attend this free Symposium?

Independent Dinner Non-CME Activity
Saturday, September 16, 2017, 6:00 - 8:00 pm
Homozygous Familial Hypercholesterolemia (HoFH): An uncommonly common condition

Total

$0.00

Payment Information

Discounts are calculated on the review screen.

Cancellation Policy:
A written notice of cancellation must be received by August 15, 2017 in order to receive a refund. Cancellations received prior to this date will be honored minus a $75 administration fee. Refunds will not be honored after August 15, 2017. Telephone cancellations cannot be accepted. Cancellation refunds will be processed within 30 days after the conclusion of the Conference.

By registering for the 2017 ASPC Congress, attendee understands and agrees that attendee's name, city, and state may be shared with other attendees and exhibitors. By allowing an exhibitor to scan the conference badge, attendee understands, agrees and consents to the sharing of attendee's contact information with the company that scanned the conference badge.

By registering for this Conference, I also give ASPC the right to publish all photos, videos, etc. taken at this Conference.

Agenda

Chair: Seth Baum, MD, FASPC
Co-Chair: Peter Toth, MD, PhD, FASPC

Friday, September 15, 2017

4:00 - 4:10 PM
Welcome and Overview
Amit Khera, MD, FASPC and Seth Baum, MD, FASPC
SESSION 1
4:10 - 4:20 PM
Audience Response Questions
4:20 - 4:45 PM
Lessons in Preventive Cardiology Learned from Epidemiology: Framingham and Beyond
Nathan Wong, PhD, FASPC
4:45 - 5:20 PM
Keynote Address Lecture
The Present and Future of PCSK9: FOURIER and Beyond

Robert Giugliano, MD
5:20 - 5:45 PM
Incorporating Recent Data into Clinical Practice and Cholesterol Guidelines
Jennifer Robinson, MD
5:45 - 6:00 PM
Question and Answer Panel Discussion and Audience Response Questions
6:00 - 7:00 PM
Welcome Reception with Exhibitors

Saturday, September 16, 2017

SESSION 2
7:15 - 9:00 PM
ASPC 2017 Town Hall Series - PCSK9 Inhibitor Access Barriers: Issues and Recommendations: Improving the Access Process for Patients, Clinicians and Payers
7:00 - 8:00 AM
Breakfast with Exhibitors
8:00 - 8:15 AM
Welcome and Audience Response Questions
8:15 - 8:40 AM
Heart Failure with Preserved Ejection Fraction: Mechanisms and Management
Jay Cohn, MD
8:40 - 9:05 AM
Screening for Atrial Fibrillation: Ready for Prime Time?
Mintu Turakhia, MD
9:05 - 9:30 AM
Hypertension Management: What’s the Right Number
Jay Cohn, MD
9:30 - 9:55 AM
Question and Answer Panel Discussion and Audience Response Questions
9:55 - 10:10 AM
Refreshment Break with Exhibitors
SESSION 3
10:10 - 10:20 AM
Audience Response Questions
10:20 - 10:45 AM
High Sensitivity Troponin in Prevention and Risk Stratification: How and When to Use
James de Lemos, MD
10:45 - 11:10 AM
HDL in Flux: New Ways to Think About an Old Lipoprotein
Sergio Fazio, MD
11:10 - 11:35 AM
CV Effects of Newer Diabetic Agents: What's the First Line for Diabetes Care?
Yehuda Handelsman, MD
11:35 AM - 12:00 PM
Question and Answer Panel Discussion and Audience Response Questions
12:00 - 1:00 PM
Lunch with Exhibitors
SESSION 4
1:00 - 1:20 PM
Young Investigator Presentation
1:20 - 1:40 PM
Young Investigator Presentation
1:40 - 2:00 PM
Young Investigator Presentation
SESSION 5
2:00 - 2:10 PM
Audience Response Questions
2:10 - 2:35 PM
Nanette K. Wenger Distinguished Lecture
Adding Competence to Our Approach in Treating Heart Disease in Women: Why We Need Specialized Care for Women’s Hearts and Vessels

Martha Gulati, MD, FASPC
2:35 - 3:00 PM
Replacing Hormones in Men and Women: Déjà vu all Over Again?
Howard Weintraub, MD, FASPC
3:00 - 3:25 PM
Weight Loss Counseling and Medications: Optimal Strategies for Success
Jaime Almandoz, MD
3:25 - 3:50 PM
Question and Answer Panel Discussion and Audience Response Questions
3:50 - 4:05 PM
Refreshment Break with Exhibitors
SESSION 6
4:05 - 4:30 PM
Case Study 1
Martha Gulati, MD, FASPC
4:30 - 4:55 PM
Case Study 2
Patrick Moriarty, MD
4:55 - 5:20 PM
Case Study 3
Yehuda Handelsman, MD
6:00 - 8:00 PM
Independent Satellite Symposium
Homozygous Familial Hypercholesterolemia (HoFH): An uncommonly common condition

This event is not part of the ASPC 2017 Congress, as planned by the ASPC Education Committee and is not being certified for CME

Sunday, September 17, 2017

SESSION 7
7:00 - 8:00 AM
Breakfast
8:00 - 8:15 AM
Welcome and Audience Response Questions
8:15 - 8:40 AM
Assessing LDL: Is it apoB, LDL-P, or simply LDL-C?
Allan Sniderman, MD
8:40 - 9:05 AM
Hypertriglyceridemia: From Mild to FCS - What to Do?
Sergio Fazio, MD
9:05 - 9:30 AM
Reemergence of Lipoprotein a: Current Recommendations and Evolving Treatments
Patrick Moriarty, MD
9:30 - 9:55 AM
Question and Answer Panel Discussion and Audience Response Questions
9:55 - 10:10 AM
Refreshment Break
SESSION 8
10:10 - 10:20 AM
Audience Response Questions
10:20 - 10:45 AM
Role of Atherosclerosis Imaging in Primary Prevention
Todd Villines, MD, FSCCT
10:45 - 11:10 AM
Smoking Cessation in the Modern Era: From Pills, Patches and Policy, to Vaping
Michael Cummings, PhD, MPH
11:10 - 11:40 AM
Great Debate in Preventive Cardiology
Pro: Advanced Lipoprotein Testing – A Key Tool for the Preventive Cardiologist

Allan Sniderman, MD
Con: Advanced Lipoprotein Testing – More Hype than Help
Jennifer Robinson, MD
11:40 AM - 12:00 PM
Question and Answer Panel Discussion and Audience Response Questions
12:00 - 12:10 PM
Closing Remarks
Seth Baum, MD, FASPC

Faculty

Amit Khera, MD, FASPC
Congress Chair
Director, Preventive Cardiology
UT Southwestern Medical Center at Dallas
Dallas, TX

Seth Baum, MD, FASPC
Congress Co-Chair
Preventive Cardiology Experts Course Co-Chair

Medical Director, Women’s Preventive Cardiology
Christine E. Lynn Women’s Health and Wellness Institute
Boca Raton Regional Hospital
Co-Founder and Chief Medical Officer, MB Clinical Research
Boca Raton, FL

Peter Toth, MD, PhD, FASPC
Preventive Cardiology Experts Course Chair
Congress Co-Chair
Director, Preventative Cardiology
CGH Medical Center
Sterling, IL
Professor, Clinical Family and Community Medicine
University of Illinois College of Medicine
Peoria, IL
Professor of Clinical Medicine
Michigan State University College of Osteopathic Medicine
East Lansing, MI
Adjunct Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Jaime Almandoz, MD
Assistant Professor, Division of Endocrinology
Weight Wellness Program
University of Texas Southwestern Medical Center
Dallas, TX

Alan Brown, MD, FASPC
Interventional Cardiologist, Midwest Heart Specialists
Director, Midwest Heart Disease Prevention Center
Clinical Associate Professor, Loyola University
Maywood, IL

Jay Cohn, MD
Professor of Medicine
Director, Rasmussen Center for CVD Prevention
University of Minnesota Medical School
Minneapolis, MN

Michael Cummings, PhD, MPH
Professor, Department of Psychiatry and Behavioral Sciences
Co-director, Tobacco Policy and Control Program, Hollings Cancer Center
Medical University of South Carolina
Charleston, SC

James de Lemos, MD
Professor of Medicine
UT Southwestern Medical Center
Dallas, TX

Daniel Duprez, MD, PhD
Donald and Patricia Garofalo Chair in Preventive Cardiology
Professor of Medicine/Cardiology
Director Lipid Clinic
Director of Research of the Rasmussen Center for Cardiovascular Disease Prevention
Professor Epidemiology and Community Health (School of Public Health)
Cardiovascular Division
University of Minnesota
Minneapolis, MN

Sergio Fazio, MD, PhD
The William and Sonja Connor
Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR

Robert Giugliano, MD
Associate Professor of Medicine
Division of Cardiovascular Medicine
Brigham and Women’s Hospital, Harvard Medical School
Boston, MA

Martha Gulati, MD, FASPC
Chief, Division of Cardiology
Professor, Medicine
University of Arizona College of Medicine
Physician Executive Director
Banner-University Medicine Cardiovascular Institute
Phoenix, AZ

Yehuda Handelsman MD
Medical Director & Principal Investigator
Metabolic Institute of America
Tarzana, CA

Stephen Kopecky, MD, FASPC
Professor of Medicine
Consultant, Cardiovascular Diseases and Internal Medicine
Mayo Clinic
Rochester, MN

Patrick Moriarty, MD
Professor of Medicine
Director, Clinical Pharmacology/Atherosclerosis and Lipid-apheresis Center
University of Kansas Medical Center
Kansas City, KS

Jennifer Robinson, MD, MPH
Professor, Director, Preventive Intervention Center
College of Public Health
University of Iowa
Iowa City, IA

Allan Sniderman, MD, FRSC
Edwards Professor of Cardiology
Professor of Medicine
McGill University
Montreal, QC

Laurence Sperling, MD, FASPC
Professor of Medicine (Cardiology)
Director, Emory Heart Disease Prevention Center
Professor of Global Health
Rollins School of Public Health
Emory University
Atlanta, GA

Mintu Turakhia, MD
Senior Director of Research and Innovation, Center for Digital Health
Stanford University School of Medicine
Chief, Cardiac Electrophysiology
VA Palo Alto Healthcare System
Stanford, CA

Todd Villines, MD
Director, Cardiovascular Research and Cardiac CT Programs
Cardiology Fellowship Director, Walter Reed National Military Medical Center
Professor of Medicine, Uniformed Services University of the Health Sciences
Bethesda, MD

Howard Weintraub, MD, FASPC
Clinical Professor of Medicine
New York University School of Medicine
Clinical Director, NYU Center for the Prevention of
Cardiovascular Disease
New York, NY

Peter Wilson, MD
Professor of Medicine, Division of Cardiology
Emory University School of Medicine
Professor of Public Health, Rollins School of Public Health
Director, Epidemiology and Genomic Medicine
Atlanta VA Medical Center
Atlanta, GA

Nathan Wong, PhD, FASPC
Professor and Director
Heart Disease Prevention Program, Division of Cardiology
University of California, Irvine
Irvine, CA

Accreditation

Congress Accreditation

Statement of Need
Important advances in the diagnosis and treatment of atherosclerotic cardiovascular disease continue to emerge, and these advances must be consistently implemented into clinical practice to provide the best care for patients. This congress is designed to educate clinicians on state-of-the-art care for atherosclerotic cardiovascular disease. Expert faculty will cover a wide range of topics on the diagnosis, treatment and prevention of atherosclerotic cardiovascular disease, and participants will return to their practice equipped with the latest evidence and practical information to improve patient outcomes.

Target Audience 
All healthcare professionals involved in the diagnosis, treatment, prevention and intervention of atherosclerotic cardiovascular disease, including physicians, pharmacists, nurse practitioners, nurses, physician assistants, dietitians, fellows and trainees.

Learning Objectives
Upon completion of the educational activity, participants should be able to:

Session 1:

  • Assess the implications of clinical trial outcomes for the future of preventive cardiology.
  • Apply guidelines into clinical practice.
  • Explore the potential applications of PCSK9-based therapies for LDL-C reduction.

Session 2:

  • Critically evaluate emerging evidence on heart failure management.
  • Discuss the rationale for diagnostic screening of patient with atrial fibrillation.
  • Describe effective interventions to maximize blood pressure control in patients with hypertension.

Session 3:

  • Assess cardiac troponin testing and utility for prevention and risk stratification.
  • Review recent advances within HDL science, including limitations of HDL as a biomarker, HDL dysfunction, and genetic associations of HDL lipoproteins with cardiovascular disease.
  • Discuss how different diabetes medications can affect cardiac outcomes.

Session 4: Young Investigator Poster Presentations (Non-CME)

Session 5:

  • Review strategies for improved diagnosis and treatment of heart disease in women.
  • Outline evidence-based benefits and potential risks of hormone replacement therapy in men and women.
  • Discuss strategies to initiate weight loss in patients who are overweight or obese.

Session 6:

  • Review appropriate therapeutic interventions in complex clinical scenarios.

Session 7:

  • Compare and contrast the utility of risk markers associated with LDL.
  • Describe pharmacologic and non-pharmacologic therapies used for the treatment of dyslipidemia and the management of hypertriglyceridemia.
  • Evaluate the use of lipoprotein (a) for CVD detection and treatment.

Session 8:

  • Review the use of imaging modalities for primary prevention of CVD.
  • Describe historical and recent trends in tobacco use behaviors and interventions to reduce use.
  • Assess the role of advanced lipid testing in preventive cardiology.

 

CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and The American Society for Preventive Cardiology. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 12.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Nurses
AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is awarded 12.75 Contact Hours.

Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and The American Society for Preventive Cardiology.

Florida Nurses 
AKH Inc., Advancing Knowledge in Healthcare is an approved provider for nursing continuing education by the Florida Board of Nursing #50-2560. 
AKH Inc., Advancing Knowledge in Healthcare designates this educational activity for 12.5 contact hour (1.25 CEU).

Pharmacists 
AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

SESSION 1:

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge‐based activity for 2.0 contact hour(s) (0.2 CEUs). UAN 0077-9999-17-017-L04-P.                                    

SESSION 2:

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge‐based activity for 1.9 contact hour(s) (0.19 CEUs). UAN 0077-9999-17-018-L04-P.                                

SESSION 3:

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge‐based activity for 1.8 contact hour(s) (0.18 CEUs). UAN 0077-9999-17-019-L04-P.                                      

SESSION 4:

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge‐based activity for 1.8 contact hour(s) (0.18 CEUs). UAN 0077-9999-17-020-L04-P.                      

SESSION 5:

Not accredited                                        

SESSION 6:   

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge‐based activity for 1.25 contact hour(s) (0.125 CEUs). UAN 0077-9999-17-021-L04-P.                                        

SESSION 7:

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge‐based activity for 1.9 contact hour(s) (0.19 CEUs). UAN 0077-9999-17-022-L04-P.                               

SESSION 8:

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge‐based activity for 2.0 contact hour(s) (0.2 CEUs). UAN 0077-9999-17-023-L04-P.

Dieticians 

AKH Inc. is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dieticians (RDs) and dietetic technicians, registered (DTRs) will receive 12.5 continuing professional education unit (CPEU) for completion of this program/material. CDR Accredited Provider #AN008. The focus of this activity is rated Level 2. Learners may submit evaluations of program/materials quality to the CDR at www.cdrnet.org.

Criteria for Success 
Statements of credit will be awarded based on the participant's attendance, participation in the pre/post-test and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.aspconline.org/cme. If you have questions about this CME/CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Commercial Support 
Full notification of commercial support will be provided in the final program.


Preventive Cardiology Experts Course Accreditation

Overview
The ASPC’s Preventive Cardiology Experts Course provides an in-depth review of the knowledge and skills necessary to successfully implement preventive therapies in cardiology.  Primary and secondary prevention strategies including management of cardiovascular risk factors, therapeutic management, and lifestyle changes will be addressed. This course provides an excellent update on core concepts in preventive cardiology, and will serve as a preparatory course for the Annual ASPC Congress on CVD Prevention and other advanced preventive cardiology training. 

Target Audience 
All healthcare professionals involved in the diagnosis, treatment, prevention and intervention of atherosclerotic cardiovascular disease, including physicians, pharmacists, nurse practitioners, nurses, physician assistants, dietitians and fellows and trainees.

Learning Objectives
Upon completion of the educational activity, participants should be able to:

Session 1: Issues in Dyslipidemia, Atherogenesis, Heart Failure and Population Health

  • Discuss the role of anti-PCSK9 monoclonal antibody therapy in LDL-C reduction to achieve cardiovascular risk reduction.
  • Identify the relationship between serum triglyceride levels and risk for cardiovascular disease.
  • Outline advancements in lipid testing and biomarkers to monitor disease activity and severity, and as guides to therapy.
  • Identify current issues and approaches to ASCVD risk assessment.
  • Critically evaluate emerging evidence on heart failure management.

Session 2: Hypertension, Diabetes, Obesity and Chronic Kidney Disease

  • Review antihypertensive therapies to reduce blood pressure and decrease CVD risk.
  • Describe emerging and novel treatment strategies for diabetes.
  • Apply new clinical insights for patients with chronic kidney disease.
  • Discuss strategies to initiate weight loss in patients who are overweight or obese.

Session 3: Coronary Artery Disease

  • Review the use of imaging and stress testing for the screening and prevention of ASCVD.
  • Describe the role of coronary stent placement in preventive medicine.

Session 4: Anticoagulation and Antiplatelet Therapy

  • Review the use of anticoagulation therapy for patients with atrial fibrillation.
  • Summarize clinical data on existing and emerging anticoagulant and antiplatelet therapies for primary and secondary prevention.

Session 5: Gender-Related Issues in Cardiovascular Disease

  • Evaluate the controversies regarding testosterone use and cardiovascular disease risk
  • Review gender-specific approaches to the identification and diagnosis of myocardial ischemia in women.

 

CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

 

 

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and The American Society for Preventive Cardiology. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 10.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Nurses
AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is awarded 10.1 Contact Hours.

Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and The American Society for Preventive Cardiology.

Florida Nurses 
AKH Inc., Advancing Knowledge in Healthcare is an approved provider for nursing continuing education by the Florida Board of Nursing #50-2560. 
AKH Inc., Advancing Knowledge in Healthcare designates this educational activity for 10 contact hour (.10 CEU).

Pharmacists 
AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

 

Session 1: Issues in Dyslipidemia, Atherogenesis, Heart Failure and Population Health

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge‐based activity for 3.75 contact hour(s) (0.375 CEUs). UAN 0077-9999-17-011-L04-P.

Session 2: Hypertension, Diabetes, Obesity and Chronic Kidney Disease                 

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge‐based activity for 2.5 contact hour(s) (0.25 CEUs). UAN 0077-9999-17-012-L04-P.

Session 3: Coronary Artery Disease

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge‐based activity for 1.25 contact hour(s) (0.125 CEUs). UAN 0077-9999-17-013-L04-P.

Session 4: Anticoagulation and Antiplatelet Therapy

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge‐based activity for 1.25 contact hour(s) (0.125 CEUs). UAN 0077-9999-17-014-L04-P.

Session 5: Gender-Related Issues in Cardiovascular Disease

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge‐based activity for 1.75 contact hour(s) (0.175 CEUs). UAN 0077-9999-17-015-L04-P.

Dieticians

AKH Inc. is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dieticians (RDs) and dietetic technicians, registered (DTRs) will receive 10 continuing professional education unit (CPEU)     for completion of this program/material. CDR Accredited Provider #AN008. The focus of this activity is rated Level 2. Learners may submit evaluations of program/materials quality to the CDR at www.cdrnet.org.

Criteria for Success 
Statements of credit will be awarded based on the participant's attendance, participation in the pre/post-test and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.aspconline.org/cme. You must participate in the entire activity to receive credit. If you have questions about this CME/CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Commercial Support 
Full notification of commercial support will be provided in the final program.

PC Expert's Course

Thursday, September 14, 2017

1:00 – 1:10 PM

Welcome and Overview

1:10 – 1:25 PM

Pre-test via Audience Response System

SESSION 1: Issues in Dyslipidemia, Atherogenesis, Heart Failure and Population Health

1:25 – 1:55 PM

Familial Hypercholesterolemia and the use of PCSK9 Monoclonal Antibodies
Laurence Sperling, MD, FASPC

1:55 – 2:25 PM

Hypertriglyceridemia: Is it a CV Risk factor and How Can it Be Treated?
Seth Baum, MD, FASPC

2:25 – 2:40 PM

Refreshment Break

2:40 – 3:10 PM

Integrating Advanced Lipid Testing and Cardiovascular Biomarkers in Assessment and Treatment
Stephen Kopecky, MD, FASPC

3:10 – 3:40 PM

ASCVD Risk Assessment: Global Risk Scoring and Evaluating for Subclinical Atherosclerosis
Nathan Wong, PhD, FASPC

3:40 – 4:10 PM

State of the Art Management of Heart Failure
Seth Baum, MD, FASPC

4:10 – 4:40 PM

Role of Inflammation in Atherogenesis
Peter Toth, MD, PhD, FASPC

4:40 – 5:00 PM

Question and Answer Panel Discussion

Friday, September 15, 2017

8:00 – 8:05 AM

Welcome and Overview

SESSION 2: Hypertension, Diabetes, Obesity, and Chronic Kidney Disease

8:05 – 8:35 AM

State of the Art Management of Hypertension
Daniel Duprez, MD, PhD

8:35 – 9:05 AM

Intelligent Patient Specific Drug Choices in the Management of Non-insulin-dependent Diabetes Mellitus
Peter Wilson, MD

9:05 – 9:35 AM

Diagnosis and Management of Chronic Kidney Disease
Daniel Duprez, MD, PhD

9:35 – 10:05 AM

Obesity and the Facilitation of Weight Loss
Jaime Almandoz, MD

10:05 – 10:25 AM

Question and Answer Panel Discussion

10:25 – 10:40 AM

Refreshment Break

SESSION 3: Coronary Artery Disease

10:40 – 11:10 AM

Integrating Imaging and Stress Testing in Assessment and Treatment
Amit Khera, MD, FASPC

11:10 – 11:40 AM

Coronary Stenting: Is it Really Preventive?
Alan Brown, MD, FASPC

11:40 – 11:50 AM

Question and Answer Panel Discussion

11:50 – 12:40 PM

Lunch

SESSION 4: Anticoagulation and Antiplatelet therapy

12:40 – 1:10 PM

Atrial Fibrillation: Management and Anticoagulation
Stephen Kopecky, MD, FASPC

1:10 – 1:40 PM

Antiplatelet Agents in Primary and Secondary Prevention: When are They Indicated?
Peter Toth, MD, FASPC

1:40 – 1:50 PM

Question and Answer Panel Discussion

SESSION 5: Gender-Related Issues in Cardiovascular Disease

1:50 – 2:20 PM

Testosterone Supplementation and Risk of Cardiovascular Events – What do you Tell a Man?
Howard Weintraub, MD, FASPC

2:20 – 2:50 PM

Evaluating Chest Pain and Myocardial Ischemia in Women
Martha Gulati, MD, FASPC

2:50 – 3:00 PM

Question and Answer Panel Discussion

3:00 – 3:30 PM

Post-test via Audience Response System and Closing Remarks

Agenda subject to change.

Venue

The Westin Fort Lauderdale Beach
321 North Ft. Lauderdale Beach Blvd
Fort Lauderdale, Florida 33304

Venue Hotel - Westin Fort Lauderdale Beach

Join us at the Westin Fort Lauderdale Beach from September 15-17, and enjoy some of South Florida’s most spectacular soft sand beaches with blue waters of the Atlantic Ocean. The resort has an abundance of activities and amenities, so don’t miss out on this great opportunity!  We have made special arrangements with the resort for Congress attendees to receive discounted room reservations starting at $179/night plus taxes. Room reservations can be made online by clicking here.  The ASPC room block will be available until August 15th or until the block fills.  

A discounted rate for Valet parking has been confirmed at $28 plus tax and self parking has been confirmed at $12 plus tax.  Be sure to mention the ASPC Congress.

Special Events

hide

Abstracts

Abstract Submission

The 2017 ASPC Abstract Committee invites the submission of abstracts to be presented at the 2017 Congress on Cardiovascular Disease Prevention September 15–17, 2017, at the Westin Fort Lauderdale Beach. Submitted abstracts will be considered for the poster hall and the top three Young Investigator abstracts with be picked for an oral presentation during the abstract session at the meeting.

All abstracts must be submitted online via the ASPC abstract submission website using the online submission form. Please be sure to read all instructions, information, and policies closely.

Important Dates

Abstract Submission Deadline
Monday, June 5, 2017
5:00 p.m. EST

Abstract Acceptance Notification
Wednesday, July 5, 2017

Presenting Author Registration Deadline for CVD Prevention Conference
Tuesday, August 1, 2017

Awards

ASPC Young Investigator Awards
Young Investigators (in training students, residents, and fellows or members in practice for <5 years) will have the chance to compete for the ASPC's Young Investigator Award. Cash prizes of $750, $500, and $250 will be presented to the top three Young Investigator Winners. In addition, the top three Young Investigator abstracts with be selected for an oral presentation.

Awards Disclaimer
If you are the recipient of one of our Young Investigator Awards, you are required to register and attend the 2017 Congress on Cardiovascular Disease Prevention, as well as attend all abstract-related responsibilities. These responsibilities include hanging your poster in the Poster Hall, standing by your poster in the poster hall during the designated time, as well as attend the oral presentation session. If you fail to attend these events, your prize and travel money could be revoked and you could be blacklisted from future abstract awards.

Presentation Methods

All accepted abstracts will be displayed in the Poster Hall.

The ASPC Abstract Committee will select three Young Investigator abstracts to be presented during the oral abstract session on Saturday, September 16, 2017. Authors will have 20 minutes to present their research (15 minutes to present and 5 minutes for questions and answers).

Abstract Submission Instructions

Please read through the submission instructions below before preparing your abstract:

  1. Read the General Information and Policies for the submission of an abstract.
  2. Write your abstract, following the Abstract Guidelines.
  3. Select a Topic that best relates to your abstract.
  4. Review the Acceptance and Presentation Process for abstracts.
  5. Submit your abstract through the Online Abstract Submission Form button.
  6. Register to attend the 2017 Congress on Cardiovascular Disease Prevention (ASPC staff will contact you with a meeting registration form to register for the meeting if your abstract has been approved).

General Information and Policies

  • You may complete your abstract submission over multiple sessions. As you will see, there will be a point in the process when you MUST finalize your abstract and make a FINAL submission. Please note that if you do not mark your abstract as complete and make a FINAL submission, it will NOT be considered. Take note of any deadlines under the appropriate call for abstracts and be sure to complete the process before that date.
  • Do not CREATE your abstract in the submission system, but rather create your abstract in a separate Word document and COPY and PASTE it into the abstract submission system. This way, you will not have lost your abstract in the event of disconnection from the Internet, etc. Be sure to check for errors when pasting. Certain special characters may be changed by the browser.
  • If you are currently a member of the ASPC, we will prefill your address information for you in the online submission form based on your current aspconline.org account information profile. Note that changes made here will apply to your abstract only and WILL NOT BE APPLIED to your ASPC member record or aspconline.org account.
  • The lead author must register for the 2017 Congress on Cardiovascular Disease Prevention to ensure his or her abstract(s) are included in onsite materials. Deadline for author registration is Tuesday, August 1, 2017. Lead authors MUST BE registrants at the ASPC Congress on Cardiovascular Disease Prevention. Authors who are not members of the ASPC must pay the non-member registration fee or can apply for membership here.
  • To submit an abstract, all of the authors listed on the abstract must approve the final version. In addition, each author listed on the abstract should have made a substantial contribution to it, such as 1) contributing to the conception and design of the study and the acquisition of data; 2) analysis and interpretation of the data; and/or 3) drafting the poster and/or revising it critically for important intellectual content. Full disclosures must be provided for each author. These requirements are taken seriously by ASPC and any failure to fully comply with these requirements may result in an abstract being withdrawn from the ASPC abstracts program.
  • It is the responsibility of the lead author to ensure that his or her abstract is submitted correctly.
  • Abstracts will be reviewed by the appointed ASPC Abstracts Review Committee Member.
  • Faxed, emailed or mailed hard-copy abstracts or abstracts sent on a CD/disc WILL NOT be accepted. If you are unable to submit via the website, please contact the ASPC Annual Meeting Staff:

    Contact: Kelsey Tomaselli
    Phone: 904-309-6217
    Fax: 904-998-0855
    Email: posters@aspconline.org

Disclaimer

The ASPC will not be responsible for abstract submissions not received via the website or for submission errors caused by Internet service outages, hardware or software delays, power outages, or unforeseen events.

ABSTRACT GUIDELINES

Content Guidelines

Abstracts for poster entries submitted for competition can only be accepted electronically and must adhere to the following guidelines:

  • Abstracts are limited to 350 words. (Word count excludes the abstract title, author names, and affiliations.)
  • Abstracts must be divided into sections: Title, Background/Synopsis, Objectives/Purpose, Design/Methods, Results, and Conclusion that states the importance and potential implications of the observations.
  • Abstracts must be proofread carefully to avoid errors before submission.
  • Abstracts must contain generic drug names only.
  • Abstracts must be submitted in clear English with accurate grammar and spelling of a quality suitable for publication.
  • Lead and secondary authors must disclose all financial relationships.
  • Any funding support for the research must be disclosed.
  • Encore research is eligible for submission but the original date and location of presentation of the research must be disclosed in the application.

Checklist

The purpose of the abstract is to define the precise subject of the presentation to an audience. Below you will find a checklist for abstract preparation. All abstracts are considered equally for selection, and the quality of the abstract is the single most important factor in the Committee's decision.

You will be asked for the following:

  • Title
  • Background/Synopsis - A concise description of your subject matter and prior work in this area.
  • Objective/Purpose - The question your material answers or the hypothesis that it tests.
  • Methods - The experimental design or technique employed.
  • Results - Outcomes & measurements, with statistical significance, if appropriate
  • Conclusion - Conclusions, clinical pertinence, and value or for Workshops and Presentations, the prevailing point of view.
  • Proofread - Make sure to proofread your abstract. Misspellings and typographical errors reflect badly on your scientific work. Prepare to substitute plain text for special characters as these characters may not be rendered reliably (i.e., plus or minus for ±, alpha for a etc.)
  • Authors - For each author you must provide first and last name, city and state as well as preliminary financial disclosure information. If you would like to be considered for oral presentation, the Primary Author should also upload a brief paragraph describing their qualifications in the chosen subject area and/or a CV.
  • Supplemental Materials - Supplementary materials (figures, tables, illustrations) will not be published along with abstracts on the CLC website. If you do have supporting materials, we will include a link to them in the published abstract, but they will be housed on the ASPC website for view.

Abstract Submission Topics

To ensure your abstract receives proper consideration, the abstract must relate to an appropriate topic in the field of Cardiology and cardiovascular disease prevention. Abstract authors will be required to indicate which topic BEST matches the content of their abstract. Topics for the 2017 ASPC Congress on Cardiovascular Disease Prevention are:

  • ASCVD Risk Factors
  • ASCVD Risk Assessment
  • ASCVD Risk Reduction
  • ASCVD Prevention – Primary and Secondary
  • Preventive Cardiology Best Practices – clinic operations, team approaches, outcomes research
  • Metabolic Syndrome
  • Diabetes
  • Obesity
  • Novel Biomarkers
  • Pharmacologic Therapy
  • Nutrition/Exercise
  • ASCVD in Women
  • ASCVD in Special Populations
  • Heart Failure
  • Ischemic Stroke
  • Peripheral Artery Disease
  • Alterative and Complimentary Approaches
  • Rehabilitation
  • Other

If you do not see an appropriate topic listed above that best relates to your abstract, please contact the ASPC office at posters@aspconline.org or call 904-309-6235.

Acceptance and Presentation Process

Abstract grading is blinded and abstracts are pre-screened and selected by ASPC judges on the basis of quality and merit. You will be notified by Wednesday, July 5, 2017, if your poster is accepted. All lead poster authors are required to register for the 2017 Congress on Cardiovascular Disease Prevention September 15–17, 2017, at the Westin Fort Lauderdale Beach to field questions from ASPC meeting attendees.

*Expenses related to airfare, lodging, and social events/guest fees are the responsibility of the presenter. Special programs may be available for trainees, fellows, and young investigators — see Young Investigator Award.

Poster guidelines will be provided to lead authors by July 5, 2017.

Questions? Contact the ASPC office at posters@aspconline.org or call 904-309-6203.

You must be logged into the ASPC Website in order to submit an abstract; however you are not currently logged into the site. Depending on the circumstances, you have one of three options:

  1. ASPC Members who have already set-up an account, please login using the boxes at the top of this (or any) aspconline.org page.
  2. ASPC Members who have not set-up an account can obtain one by writing the webmaster.
  3. Need a GUEST account? A guest account can be created for non-members. You may submit a request by clicking this Link. Please complete all contact information in the form.

Exhibitors

Held at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida, the 2017 Annual Meeting is your opportunity to interact and market your product, device or service to the American Society for Preventive Cardiology's audience. As an exhibitor, increase your presence at this meeting by taking advantage of exhibitor-only sponsorship opportunities and showcase what your company has to offer. Sponsorships and exhibits are available in different levels to guarantee your company's maximum exposure.

Download Exhibitor Prospectus

For more information regarding exhibits and sponsorships, contact Chealsea Schroeder
Email: cschroeder@aspconline.org
Phone: (904) 309-6220

Exhibit Hall Hours

hide

Virtual Exhibit Hall

Akcea Therapeutics
www.akceatx.com

Amgen
www.amgen.com

Boehringer-Ingelheim Pharmaceuticals
www.boehringer-ingelheim.com

Boston Heart Diagnostics
www.bostonheartdiagnostics.com

Kastle Therapeutics
www.kastletherapeutics.com

Kowa Pharmaceuticals America, Inc.
www.kowapharma.com

Quten Research Institute
www.qunol.com

Regeneron Pharmaceuticals
www.regeneron.com

Affiliations

Coming soon

Satellite Symposium

ASPC 2017 Town Hall Series - PCSK9 Inhibitor Access Barriers: Issues and Recommendations: Improving the Access Process for Patients, Clinicians and Payers

Non-CME/CE Dinner Symposium

Free to Attend!

In 2016, the American Society for Preventive Cardiology (ASPC) brought together various stakeholder organizations for two Town Halls: "Unraveling a Therapeutic Conundrum: Barriers to Access PCSK9 Inhibitors." ASPC and other stakeholder groups - National Lipid Association (NLA), American Association of Clinical Endocrinologists (AACE), American College of Cardiology (ACC), FH Foundation (FHF) - identified access issues and recommended pragmatic solutions. The 2017 Town Hall series reveals and explains these consensus recommendations for improving the access process for patients, clinicians and payers.

Date: Friday, September 15, 2017

Time: 7:15 - 9:00 PM

Location: Westin Fort Lauderdale Beach,  Room: Las Olas Ballroom

This activity is sponsored by Amgen Inc., Sanofi and Regeneron.

 

Homozygous Familial Hypercholesterolemia (HoFH):  An uncommonly common condition

Non-CME/CE Dinner Symposium

Free to Attend!

Discuss the latest data on the prevalence of HoFH patients, review specific patient cases to help HCPs identify potential HoFH patients in their practice, and learn how Kynamro may be an adjunctive treatment to the patients’ current lipid lowering therapies. 

Date: Satruday, September 16, 2017 

Time: 6:00 -  8:00 PM

Location: Westin Fort Lauderdale Beach

This activity is sponsored by Kastle Therapeutics, LLC.

 

How to Register:
Congress registration is not required for these symposia and there is no fee to attend. Attendees who are already registered for the Congress should email Vivian Grifantini at vgrifantini@aspconline.org to register for this program. All others should select the satellite symposium option here.

These symposia are held during the American Society for Preventive Cardiology’s 2017 Congress on Atherosclerotic Cardiovascular Disease Prevention on September 15-17, 2017 at the Westin Ft. Lauderdale Beach in Ft. Lauderdale, FL.These symposia are not part of the ASPC 2017 Congress, as planned by the ASPC Education Committee and is not being certified for CME/CE credit.

 

Promotional Support

Coming Soon

Live Streaming

hide